Case Reports

Bilateral thigh and knee pain • leg weakness • no history of trauma • Dx?

Author and Disclosure Information

 

References

What you’ll see

Symptoms typically include unilateral or bilateral prodromal pain with a sharp or achy character that is localized to the mid-thigh, upper thigh, or groin.9 If an AFF is suspected, we recommend performing a bilateral exam and obtaining radiographs.

If characteristic features are found (eg, signs of focal cortical thickening or beaking) and pain arises in the opposite limb, obtain a radiograph of the contralateral femur. If radiographs are negative but suspicion remains, order magnetic resonance imaging or a bone scan, to identify a cortical fracture line, bone and marrow edema, or hyperemia.5

Begin treatment by discontinuing bisphosphonates

Upon identification of an AFF, discontinue bisphosphonates and initiate calcium and vitamin D supplementation.5 Prophylactic surgical fixation may also be necessary to accelerate healing and prevent fracture propagation and further pain.

Bilateral intramedullary nailing image

Our patient. Due to the longevity of the symptoms and the bilateral stress fractures noted on the bone scan, our patient chose to proceed with intramedullary nailing of the bilateral femurs (FIGURES 3 and 4). On postop Day 1, she was able to ambulate using a walker and to participate in bilateral weight-bearing (as tolerated). She was discharged to a skilled nursing facility, where she progressed to full weight-bearing without aid. On follow-up (one year postop), the patient reported no residual leg pain and was able to work out 5 days per week. Radiographs of her femurs demonstrated healed fractures and stable position of the intramedullary nails.

More pronounced beaking image

THE TAKEAWAY

An increased suspicion for AFFs due to bisphosphonate use can lead to earlier diagnosis and decreased morbidity for patients. Use of femoral imaging can promote detection and reduce financial burden.

To help prevent AFFs from occurring, we recommend reevaluating the need for continued bisphosphonate therapy after 2 to 5 years of treatment. Continued surveillance is also advisable throughout the duration of their use.

ACKNOWLEDGMENT
The authors wish to acknowledge Dr. Maurice Manring for his help in preparing this manuscript.

Pages

Recommended Reading

Opioid deaths in the ED increase nationally
MDedge Family Medicine
Nonopioid analgesics have no major disadvantages vs. opioids for chronic pain
MDedge Family Medicine
Opioid prescriptions got shorter in 2017
MDedge Family Medicine
The case for being open-minded about medical marijuana
MDedge Family Medicine
Intramuscular steroid injection reduced hip OA pain up to 12 weeks
MDedge Family Medicine
MDedge Daily News: Why the barber’s chair can help hypertension
MDedge Family Medicine
Abstract: The Opioid Crisis and the Need for Compassion in Pain Management
MDedge Family Medicine
Is kratom the answer to the opioid crisis?
MDedge Family Medicine
Abstract: Don't demonise prescription opioids
MDedge Family Medicine
FDA advisors recommend lofexidine for opioid withdrawal
MDedge Family Medicine